Protocol Ledger

NCT03745287 · Phase II/III · COMPLETED

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Interventional Phase II/III clinical trial protocol NCT03745287 sponsored by Vertex Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-27 Enrollment: 63 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03745287
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)63 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03745287
Protocol FieldVerified Registry Value
NCT IdentifierNCT03745287
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment63 participants (ACTUAL)
Registered Start Date2018-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI